Format

Send to

Choose Destination
Curr Hematol Rep. 2005 Jan;4(1):51-8.

C-kit as a target in the treatment of acute myelogenous leukemia.

Author information

1
Department of Hematology Medical Oncology, Desk 35, The Cleveland Clinic Lerner College of Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA. advania@ccf.org

Abstract

Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are currently being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of de novo AMLs and 95% of relapsed AMLs. C-kit mediates proliferation and anti-apoptotic effects in AML. This review will discuss the biology of c-kit in normal and malignant hematopoiesis, and the recent clinical trials targeting c-kit in AML.

PMID:
15610660
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center